Abstract Number: 1521 • 2014 ACR/ARHP Annual Meeting
Sustained Improvements in Magnetic Resonance Imaging Outcomes with Abatacept Following the Withdrawal of All Treatment in Patients with Early Rheumatoid Arthritis
Background/Purpose: Biologic treatment can lead to improved clinical outcomes in early RA. In the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) study, abatacept (ABA) +…Abstract Number: 388 • 2014 ACR/ARHP Annual Meeting
Soluble TREM-1 Is a Biomarker of Anti-CCP-Positive, DMARD-Naive Early Rheumatoid Arthritis
Background/Purpose : Triggering receptor expressed on myeloid cells-1 (TREM-1) is a cell-surface receptor, expressed mainly on monocytes and neutrophils and involved in amplification of the inflammatory…Abstract Number: 2472 • 2014 ACR/ARHP Annual Meeting
The First, Multicenter, Double-Blind, Randomized, Parallel-Group Study of Certolizumab Pegol in Early Rheumatoid Arthritis Demonstrates Inhibition of Joint Damage Progression
Background/Purpose The efficacy and safety of certolizumab pegol (CZP)+methotrexate (MTX) therapy compared to MTX alone, in Japanese MTX-naïve early rheumatoid arthritis (RA) patients (pts) with…Abstract Number: 1411 • 2014 ACR/ARHP Annual Meeting
Psychological Distress over Time in Early Rheumatoid Arthritis: Results from a Longitudinal Study in an Early Arthritis Cohort
Background/Purpose Rheumatoid arthritis (RA) is a chronic disease with frequent psychological comorbidities, of which depression and anxiety are 2 common manifestations. We aimed to identify…Abstract Number: 362 • 2014 ACR/ARHP Annual Meeting
14-3-3η Early RA Biomarkers: Does Seronegative RA Exist?
Background/Purpose RF and ACPA are used for early diagnosis and in prediction models for the risk of RA development in arthralgia patients. There remains a…Abstract Number: 2460 • 2014 ACR/ARHP Annual Meeting
Phospho-STAT1/3 and Gene Expression Measurement in Circulating CD4+ T Cells As Diagnostic Tools in Early Autoantibody-Negative Rheumatoid Arthritis
Background/Purpose Early diagnosis of rheumatoid arthritis (RA) improves outcomes but is challenging, particularly amongst anti-citrullinated peptide auto-antibody (ACPA) negative individuals. Previously we identified an IL-6…Abstract Number: 1402 • 2014 ACR/ARHP Annual Meeting
Parameters of Periodontitis Correlate with Anti-Citrullinated Protein Antibodies and P. Gingivalis Antibody Titers in Patients with Early or Chronic Rheumatoid Arthritis
Background/Purpose Emerging evidence suggests that periodontitis and periodontal pathogens, such as Porphyromonas gingivalis (Pg), may be an environmental trigger for rheumatoid arthritis (RA). We found…Abstract Number: 361 • 2014 ACR/ARHP Annual Meeting
Citrullinated 14-3-3η Antibodies Are Specific for Early and Established RA and Are Complementary to ACPA
Background/Purpose Citrullination is a post-translational modification whereby arginine (Arg) is deiminated by PAD enzymes to form citrulline (Cit). In RA, current ACPA assays measure the…Abstract Number: 2463 • 2014 ACR/ARHP Annual Meeting
Stromal Cell Markers Are Differentially Expressed in the Synovial Tissue of Patients with Early Arthritis
Background/Purpose Previous studies have shown increased expression of stromal markers in synovial tissue (ST) of patients with established rheumatoid arthritis (RA). Here, the expression of…Abstract Number: 1388 • 2014 ACR/ARHP Annual Meeting
Prevalence and Predictive Factors of Drug-Free and Sustained Remission in Patients with Early Arthritis
Background/Purpose : Early and sustained remission has become the ultimate goal in early arthritis patients. The aim of our study was to estimate the prevalence…Abstract Number: 360 • 2014 ACR/ARHP Annual Meeting
88% of Recent Onset Polyarthritis Patients Are Positive for 14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a Favourable Prognosis
Background/Purpose The 14-3-3η protein has been described as a mechanistic marker that is detectable in serum during the very early stages of RA development. A…Abstract Number: 2417 • 2014 ACR/ARHP Annual Meeting
Is Remission Really Achievable in EARLY Rheumatoid Arthritis?
Background/Purpose: : to stress the need of routine use of US imaging in treat to target strategies aiming to achieve remission in early rheumatoid arthritis.…Abstract Number: 1383 • 2014 ACR/ARHP Annual Meeting
Disease Characteristics and RA Development in Undifferentiated Arthritis: A 2-Year Follow-up Study of 413 Patients with Arthritis of Less Than 16 Weeks Duration
Background/Purpose: Correct identification of the subset of patients with undifferentiated arthritis (UA) who will develop rheumatoid arthritis (RA) is important to enable initiation of appropriate…Abstract Number: 374 • 2014 ACR/ARHP Annual Meeting
IL-33 and Soluble ST2 Levels As Novel Predictors for Remission and Progression of Carotid Plaque in Early Rheumatoid Arthritis: A Prospective Study
Background/Purpose Clinical remission is achievable for patients with early rheumatoid arthritis (ERA). Identification of predictors for response of treatment may provide risk estimation and help…Abstract Number: 2381 • 2014 ACR/ARHP Annual Meeting
Adherence to a Treat-to-Target (T2T) Strategy in Early Rheumatoid Arthritis. Is It Feasible in Daily Clinical Practice?
Background/Purpose : The treat-to-target (T2T) strategy has become the new paradigm for the treatment of Rheumatoid Arthritis (RA); however the question is whether this strategy…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 18
- Next Page »